CMB reports grants and personal fees from Abbott Diagnostic, personal fees from AstraZeneca, personal fees from Amarin, grants and personal fees from Amgen, grants and personal fees from Esperion, personal fees from Matinas BioPharma, personal fees from Pfizer, grants and personal fees from Novartis, grants and personal fees from Regeneron, grants and personal fees from Roche Diagnostic, personal fees from Sanofi-Synthelabo, grants from the US National Institutes of Health, grants from the American Heart Association, grants from the American Diabetes Association, personal fees from Althera, grants and personal fees from Novo Nordisk, grants from Akcea, personal fees from Denka Seiken, personal fees from Gilead, personal fees from Genentech, personal fees from Illumina, grants and personal fees from Arrowhead, personal fees from New Amsterdam, grants from Ionis, grants and personal fees from Merck, personal fees from 89Bio, and personal fees from Alnylam Pharmaceuticals, all outside the area of work commented on here. LAA has received support from the American Diabetes Association (grant #1-21-CMF-003). LAA declares no competing interests.